MDD
MCID: MLD017
MIFTS: 33

Mal De Debarquement Syndrome (MDD)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Mal De Debarquement Syndrome

MalaCards integrated aliases for Mal De Debarquement Syndrome:

Name: Mal De Debarquement Syndrome 20
Mal De Debarquement 20 58 70
Sickness of Disembarkment 20 58
Disembarkment Syndrome 20 58
Mdds 20 58
Mdd 58

Characteristics:

Orphanet epidemiological data:

58
mal de debarquement
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

MESH via Orphanet 45 C537840
ICD10 via Orphanet 33 H81.8
UMLS via Orphanet 71 C1608983
Orphanet 58 ORPHA210272
UMLS 70 C1608983

Summaries for Mal De Debarquement Syndrome

GARD : 20 Mal de debarquement syndrome is a neurological disorder that most commonly develops following an ocean cruise or other type of water travel and less commonly following air travel, train travel, or other motion experiences. The symptoms typically reported include: persistent sensation of motion such as rocking, swaying, and/or bobbing, difficulty maintaining balance, anxiety, fatigue, unsteadiness, and difficulty concentrating. The symptoms may be last anywhere from a month to years. Symptoms may or may not go away with time; however, they may reoccur following another motion experience or during periods of stress or illness. Although there is no known cure for mal de debarquement syndrome, there is evidence that some patients have responded positively to antidepressants or anti- seizure medications. Customized vestibular therapy and exercise routines may also be effective.

MalaCards based summary : Mal De Debarquement Syndrome, also known as mal de debarquement, is related to major depressive disorder and depression. The drugs Sertraline and Buspirone have been mentioned in the context of this disorder. Affiliated tissues include eye, cortex and lung, and related phenotypes are abnormality of eye movement and diplopia

Wikipedia : 73 Mal de debarquement (or mal de débarquement) syndrome (MdDS, or common name disembarkment syndrome) is a... more...

Related Diseases for Mal De Debarquement Syndrome

Diseases related to Mal De Debarquement Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 11.7
2 depression 11.2
3 mitochondrial dna depletion syndrome 11.1
4 mitochondrial dna depletion syndrome 4a 11.1
5 mental depression 10.9
6 migraine with or without aura 1 10.5
7 post-traumatic stress disorder 10.4
8 motion sickness 10.4
9 pathologic nystagmus 10.4
10 personality disorder 10.2
11 mood disorder 10.2
12 hand skill, relative 10.2
13 headache 10.2
14 generalized anxiety disorder 10.2
15 acute stress disorder 10.2
16 ataxia and polyneuropathy, adult-onset 10.2
17 major affective disorder 8 10.1
18 major affective disorder 9 10.1
19 sexual disorder 10.1
20 bipolar disorder 10.1
21 avoidant personality disorder 10.1
22 alcohol use disorder 10.1
23 constipation 10.0
24 severe combined immunodeficiency 10.0
25 schizophrenia 9.9
26 macular degeneration, age-related, 1 9.9
27 anxiety 9.9
28 microvascular complications of diabetes 5 9.9
29 nasopharyngitis 9.9
30 lung disease 9.9
31 chronic pain 9.9
32 mpv17-related mitochondrial dna maintenance defect 9.9
33 alcohol dependence 9.8
34 type 2 diabetes mellitus 9.8
35 medulloblastoma 9.8
36 obsessive-compulsive disorder 9.8
37 pulmonary fibrosis, idiopathic 9.8
38 lymphoma, hodgkin, classic 9.8
39 body mass index quantitative trait locus 11 9.8
40 body mass index quantitative trait locus 9 9.8
41 body mass index quantitative trait locus 8 9.8
42 lymphoma, non-hodgkin, familial 9.8
43 body mass index quantitative trait locus 4 9.8
44 body mass index quantitative trait locus 10 9.8
45 body mass index quantitative trait locus 7 9.8
46 hamamy syndrome 9.8
47 body mass index quantitative trait locus 12 9.8
48 body mass index quantitative trait locus 14 9.8
49 leukemia, acute lymphoblastic 9.8
50 body mass index quantitative trait locus 18 9.8

Graphical network of the top 20 diseases related to Mal De Debarquement Syndrome:



Diseases related to Mal De Debarquement Syndrome

Symptoms & Phenotypes for Mal De Debarquement Syndrome

Human phenotypes related to Mal De Debarquement Syndrome:

58 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of eye movement 58 Occasional (29-5%)
2 diplopia 58 Occasional (29-5%)
3 vomiting 58 Occasional (29-5%)
4 fatigue 58 Occasional (29-5%)
5 anxiety 58 Occasional (29-5%)
6 vertigo 58 Frequent (79-30%)
7 gait imbalance 58 Frequent (79-30%)
8 migraine 58 Occasional (29-5%)
9 headache 58 Occasional (29-5%)
10 brain imaging abnormality 58 Excluded (0%)
11 unsteady gait 58 Frequent (79-30%)
12 vestibular dysfunction 58 Excluded (0%)
13 confusion 58 Occasional (29-5%)
14 blurred vision 58 Occasional (29-5%)
15 postural instability 58 Frequent (79-30%)
16 nausea 58 Occasional (29-5%)
17 eyelid fasciculation 58 Occasional (29-5%)

Drugs & Therapeutics for Mal De Debarquement Syndrome

Drugs for Mal De Debarquement Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sertraline Approved Phase 4 79617-96-2 68617
2
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
3
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
4
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
5
Zolpidem Approved Phase 4 82626-48-0 5732
6
Promethazine Approved, Investigational Phase 4 60-87-7 4927
7
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
9
Ethanol Approved Phase 4 64-17-5 702
10
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
11
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
12
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
13
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
14
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
15
Citalopram Approved Phase 4 59729-33-8 2771
16
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
17
Lithium carbonate Approved Phase 4 554-13-2
18
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
19
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
20
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
21
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
22
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
23
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
24
Tianeptine Investigational Phase 4 66981-73-5, 72797-41-2, 26638-66-4 3075702 68870
25
Dexetimide Withdrawn Phase 4 21888-98-2
26 abobotulinumtoxinA Phase 4
27 Botulinum Toxins, Type A Phase 4
28 Botulinum Toxins Phase 4
29 Quetiapine Fumarate Phase 4 111974-72-2
30 GABA Agonists Phase 4
31 Estrogens Phase 4
32 Hormone Antagonists Phase 4
33 Central Nervous System Stimulants Phase 4
34 Desvenlafaxine Succinate Phase 4 386750-22-7
35 Antioxidants Phase 4
36 Protective Agents Phase 4
37 Sympathomimetics Phase 4
38 adderall Phase 4
39 Antidepressive Agents, Tricyclic Phase 4
40 Endorphins Phase 4
41 Analgesics, Opioid Phase 4
42 Duloxetine Hydrochloride Phase 4
43 Analgesics, Non-Narcotic Phase 4
44 Antirheumatic Agents Phase 4
45 Cyclooxygenase 2 Inhibitors Phase 4
46 Anti-Inflammatory Agents Phase 4
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Dopamine Agents Phase 4
50 Adrenergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 236)
# Name Status NCT ID Phase Drugs
1 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
2 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
3 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
4 Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators Completed NCT02809677 Phase 4 Escitalopram;Venlafaxine XR;Bupropion XR;Sertraline;Mirtazapine;Buspirone;Quetiapine;Aripiprazole;Lithium
5 Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD Completed NCT00536471 Phase 4 Duloxetine hydrochloride;Placebo
6 Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram Completed NCT00296179 Phase 4 zolpidem tartrate
7 A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder Completed NCT00960986 Phase 4 Duloxetine hydrochloride
8 Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression Completed NCT01557946 Phase 4 citalopram
9 Effect of Bupropion on Seizure Threshold in Depressed Patients Completed NCT03126682 Phase 4 Wellbutrin SR 300Mg Extended-Release Tablet
10 Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Completed NCT01477203 Phase 4 Escitalopram
11 Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen Completed NCT00626340 Phase 4 MDD diagnosis and Estrogen treatment;MDD diagnosis and Fluoxetine treatment;MDD diagnosis with both Estrogen and Fluoxetine treatment;No depression and estrogen treatment
12 Serotonin Transporter Genetic Variation and Amygdala Responses to Quetiapine and Selective Serotonin Reuptake Inhibitor Treatment in Major Depression Completed NCT02132286 Phase 4 Quetiapine XR (extended release)
13 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
14 Phase IV Pilot Study to Examine the Efficacy and Safety of Escitalopram in Doses up to 50 mg for the Treatment of Patients With Major Depressive Disorder (MDD). Completed NCT00785434 Phase 4 escitalopram
15 TRD - 2: A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD) Completed NCT00955955 Phase 4
16 A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation Completed NCT01056289 Phase 4 Desvenlafaxine Succinate Sustained-Release Formulation 50 mg;Desvenlafaxine Succinate Sustained-Release Formulation 25 mg;Placebo
17 A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
18 A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic Completed NCT02466477 Phase 4
19 Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD) Completed NCT02332954 Phase 4 vortioxetine
20 Ventrostriatal Dopamine Release and Reward Motivation in MDD Completed NCT02033369 Phase 4 Pramipexole
21 A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
22 Brainsway Deep TMS System for Treatment of Major Depressive Disorder (MDD) Using Intermittent Theta Burst Stimulation (iTBS) Protocol Completed NCT04679753 Phase 4
23 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Adjunctive, Flexible-Dose Mixed Salts Amphetamine (MSA) in Adult Outpatients With Major Depressive Disorder (MDD) Responding Inadequately to Current Antidepressant Therapy (ADT) Completed NCT02058693 Phase 4 mixed salts amphetamine
24 A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD) Completed NCT00321152 Phase 4
25 An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features. Completed NCT01477931 Phase 4 Bupropion extended release
26 Tianeptine for Treatment Resistant Depression Recruiting NCT04249596 Phase 4 Tianeptine Sodium
27 Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) Recruiting NCT04245748 Phase 4 Escitalopram;Duloxetine
28 Interventional, Open-label Effectiveness Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder Comorbid With Generalized Anxiety Disorder Recruiting NCT04220996 Phase 4 Vortioxetine
29 Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial Recruiting NCT04589143 Phase 4 Agomelatine;Placebos
30 The Effect of Celecoxib on Neuroinflammation in MDD: PET Imaging of a Novel Treatment Target With [18F]FEPPA Recruiting NCT04814355 Phase 4 Celecoxib 400 mg
31 Antidepressant Response in Older Adults With Comorbid PTSD and MDD Recruiting NCT04697693 Phase 4 Escitalopram;Duloxetine
32 A Multicenter, 180-day Pragmatic Clinical Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder Terminated NCT03643159 Phase 4 Aripiprazole or other oral antipsychotics
33 A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD) Terminated NCT01337609 Phase 4 Ganeden BC30
34 A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients Terminated NCT00926835 Phase 4 paroxetine;Escitalopram;Venlafaxine XR;Paroxetine+Bupropion;Paroxetine+Lamotrigine;Paroxetine+Lithium;Escitalopram+Mirtazapine;Escitalopram+Aripiprazole;Paroxetine + Venlafaxine XR
35 An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China Withdrawn NCT00878748 Phase 4 Effexor XR
36 Efficacy of Trial-based Cognitive Therapy and Behavioral Activation in Treatment of Depression: a Randomized Clinical Trial Unknown status NCT02624102 Phase 3 Antidepressants
37 Light and Ion Treatment to Enhance Medication Efficacy in Depression Completed NCT00958204 Phase 3 Placebo;Fluoxetine
38 A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment Completed NCT01187407 Phase 3 LY2216684;Placebo;SSRI
39 A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone Completed NCT02015546 Phase 3 Vilazodone
40 A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Completed NCT02012218 Phase 3 ADT;Brexpiprazole
41 A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period Completed NCT00051272 Phase 3 Extended-release Bupropion Hydrochloride
42 Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment. Completed NCT02013609 Phase 3 Brexpiprazole
43 A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period Completed NCT00051259 Phase 3 Extended-Release Bupropion Hydrochloride
44 An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2302E) Completed NCT00411242 Phase 3 agomelatine;placebo
45 An Open-Label Clinical Trial Evaluating Sensitivity to Change in Cognition Using the THINC-it Following Treatment With Vortioxetine in Major Depressive Disorder Completed NCT03053362 Phase 2, Phase 3 Vortioxetine
46 A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs Completed NCT02720198 Phase 3 Levomilnacipran;Quetiapine
47 Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks Completed NCT01312922 Phase 3 PNB01 fixed dose combination of pipamperone and citalopram;Citalopram;Pipamperone
48 A 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD) Completed NCT01110902 Phase 3 Agomelatine (AGO178C);Placebo
49 Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study Completed NCT01138007 Phase 3 323U66 SR 150 mg tablet;323U66 SR 150 mg placebo tablet
50 Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD) Completed NCT02709746 Phase 3 Vortioxetine 10 mg/day;Vortioxetine 20 mg/day;Fluoxetine 20 mg/day

Search NIH Clinical Center for Mal De Debarquement Syndrome

Genetic Tests for Mal De Debarquement Syndrome

Anatomical Context for Mal De Debarquement Syndrome

MalaCards organs/tissues related to Mal De Debarquement Syndrome:

40
Eye, Cortex, Lung, Amygdala, Prefrontal Cortex, Brain

Publications for Mal De Debarquement Syndrome

Articles related to Mal De Debarquement Syndrome:

(show top 50) (show all 78)
# Title Authors PMID Year
1
An uncommon cause of headache and dizziness after cruise travel: case report of Mal De Debarquement syndrome. 61
33694342 2021
2
Gathering your 'sea legs': Extended durations in an offshore environment increases postural sway excursions. 61
33677178 2021
3
Treatment of Mal de Debarquement Syndrome in a Computer-Assisted Rehabilitation Environment. 61
33604663 2021
4
Transcranial Magnetic Stimulation as Treatment for Mal de Debarquement Syndrome: Case Report and Literature Review. 61
32496300 2020
5
Mal de Debarquement Syndrome. 61
31986543 2020
6
Mal de Debarquement Syndrome: A Rare Entity. 61
32175204 2020
7
Neural Correlates of Transient Mal de Debarquement Syndrome: Activation of Prefrontal and Deactivation of Cerebellar Networks Correlate With Neuropsychological Assessment. 61
32695063 2020
8
Readaptation Treatment of Mal de Debarquement Syndrome With a Virtual Reality App: A Pilot Study. 61
33013617 2020
9
Mal de Debarquement Syndrome: A Matter of Loops? 61
33244308 2020
10
Occipital and Cerebellar Theta Burst Stimulation for Mal De Debarquement Syndrome. 61
31436631 2019
11
Approach to an experimental model of Mal de Debarquement Syndrome. 61
31049730 2019
12
Multimodal Imaging of Repetitive Transcranial Magnetic Stimulation Effect on Brain Network: A Combined Electroencephalogram and Functional Magnetic Resonance Imaging Study. 61
30803271 2019
13
Pilot study on patients with Mal de Debarquement syndrome during pregnancy. 61
31114703 2019
14
Dedication to Mingjia Dai, Ph.D. for Discovery of the First Successful Treatment of the Mal de Debarquement Syndrome. 61
31920903 2019
15
Treatment of Mal de Debarquement Syndrome in a Deployed Environment. 61
29788412 2018
16
Electrophysiological Signatures of Intrinsic Functional Connectivity Related to rTMS Treatment for Mal de Debarquement Syndrome. 61
30099627 2018
17
A new theory on GABA and Calcitonin Gene-Related Peptide involvement in Mal de Debarquement Syndrome predisposition factors and pathophysiology. 61
30220332 2018
18
Mal de Debarquement Syndrome: A Case Report. 61
30430059 2018
19
Effect of Body Positions on EEG signals in Mal de Debarquement Syndrome. 61
30440776 2018
20
Mal de Debarquement Syndrome: a survey on subtypes, misdiagnoses, onset and associated psychological features. 61
29305644 2018
21
Examination of Current Treatments and Symptom Management Strategies Used by Patients With Mal De Debarquement Syndrome. 61
30483208 2018
22
Hypothesis: The Vestibular and Cerebellar Basis of the Mal de Debarquement Syndrome. 61
29459843 2018
23
Perspective: Stepping Stones to Unraveling the Pathophysiology of Mal de Debarquement Syndrome with Neuroimaging. 61
29483889 2018
24
Sham-Controlled Study of Optokinetic Stimuli as Treatment for Mal de Debarquement Syndrome. 61
30410464 2018
25
Mal de Debarquement Syndrome: A Retrospective Online Questionnaire on the Influences of Gonadal Hormones in Relation to Onset and Symptom Fluctuation. 61
29910765 2018
26
Comprehensive Clinical Profile of Mal De Debarquement Syndrome. 61
29867709 2018
27
Resting State Functional Connectivity Signature of Treatment Effects of Repetitive Transcranial Magnetic Stimulation in Mal de Debarquement Syndrome. 61
28967282 2017
28
Management of mal de debarquement syndrome as vestibular migraines. 61
27730651 2017
29
Assessing rTMS effects in MdDS: Cross-modal comparison between resting state EEG and fMRI connectivity. 61
29060275 2017
30
Scuba diving and otology: a systematic review with recommendations on diagnosis, treatment and post-operative care. 61
28641322 2017
31
Treatment of the Mal de Debarquement Syndrome: A 1-Year Follow-up. 61
28529496 2017
32
Optimizing rTMS treatment of a balance disorder with EEG neural synchrony and functional connectivity. 61
28268279 2016
33
Randomized Single Blind Sham Controlled Trial of Adjunctive Home-Based tDCS after rTMS for Mal De Debarquement Syndrome: Safety, Efficacy, and Participant Satisfaction Assessment. 61
27117283 2016
34
The relationship between symptom severity, stigma, illness intrusiveness and depression in Mal de Debarquement Syndrome. 61
25331814 2016
35
Double-Blind Sham-Controlled Crossover Trial of Repetitive Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome. 61
27176615 2016
36
Letter to the Editor: comment and erratum to "Mal de debarquement syndrome: a systematic review". 61
27067708 2016
37
Mal de debarquement syndrome: a systematic review. 61
26559820 2016
38
Efficacy of neurostimulation to treat symptoms of Mal de Debarquement Syndrome. A preliminary study using repetitive transcranial magnetic stimulation. 61
25809585 2015
39
Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms. 61
26231281 2015
40
Mal de debarquement syndrome: new insights. 61
25726862 2015
41
Use of sensory reweighting for a woman with persistent mal de debarquement: a case report. 61
24978933 2015
42
Mal de Debarquement Syndrome: A Rare Entity-A Case Report and Review of the Literature. 61
26346344 2015
43
Voxel Based Morphometry Alterations in Mal de Debarquement Syndrome. 61
26252893 2015
44
[Mal de debarquement: a case report]. 61
25623876 2014
45
Lasting modulation effects of rTMS on neural activity and connectivity as revealed by resting-state EEG. 61
24686227 2014
46
A case of persistent dizziness after travel. 61
24566337 2014
47
Changes of symptom and EEG in mal de debarquement syndrome patients after repetitive transcranial magnetic stimulation over bilateral prefrontal cortex: a pilot study. 61
25570942 2014
48
Readaptation of the vestibulo-ocular reflex relieves the mal de debarquement syndrome. 61
25076935 2014
49
Mal de debarquement, motion sickness and the effect of an artificial horizon. 61
24594496 2014
50
Rocking dizziness and headache: a two-way street. 61
23674832 2013

Variations for Mal De Debarquement Syndrome

Expression for Mal De Debarquement Syndrome

Search GEO for disease gene expression data for Mal De Debarquement Syndrome.

Pathways for Mal De Debarquement Syndrome

GO Terms for Mal De Debarquement Syndrome

Sources for Mal De Debarquement Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....